NCT06702995 Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT06691984 Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06652607 PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer Status RECRUITING Phase N/A
NCT06632977 Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial Status RECRUITING Phase PHASE2
NCT06629779 A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. Status RECRUITING Phase PHASE3
NCT06616155 Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT06592924 Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response Status RECRUITING Phase PHASE3
NCT06576037 Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin Status RECRUITING Phase PHASE1
NCT06551324 A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06520345 The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) Status RECRUITING Phase PHASE3
NCT06499870 Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial Status RECRUITING Phase PHASE2
NCT06457919 A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT06430411 Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study Status NOT_YET_RECRUITING Phase N/A
NCT06378866 Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Status RECRUITING Phase PHASE2
NCT06332170 ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors Status RECRUITING Phase PHASE1
NCT06312670 Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer Status COMPLETED Phase PHASE2
NCT06257693 Enzalutamide Implants (Enolen) in Patients With Prostate Cancer Status RECRUITING Phase PHASE1
NCT06236139 Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT06228053 Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer Status RECRUITING Phase PHASE2
NCT06204302 An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States Status COMPLETED Phase N/A